Nathalie provides strategic DMPK & ADME discovery services, nonclinical DMPK, clinical pharmacology, and regulatory sciences for several biotechnology companies. She is also a Core Team Member of the Center of Excellence in Drug Interaction Science.

Nathalie obtained her Ph.D. in Pharmacy at Laval University, Quebec, Canada, where she studied lung cancer chemoprevention and completed a post-doctoral fellowship in drug metabolism. Nathalie has more than 20 years of experience in the pharmaceutical industry, in biotech, pharma, and CRO service. After being a DMPK lab head & project leader for multiple antiviral drug development projects at Boehringher Ingelheim, she moved to a principal DMPK scientist role at Epizyme. Most recently, she built the DMPK, bioanalytical and clinical pharmacology group at H3 Biomedicine, where she drove the strategic and tactical activities across the discovery and development space.